Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
about
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Effects of canagliflozin on weight loss in high-fat diet-induced obese mice.Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic MiceRationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Tree shrew (Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease.ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes.Review article: new treatments in non-alcoholic fatty liver disease.Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities.Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.The effect of dapagliflozin treatment on epicardial adipose tissue volume.Current and future pharmacological therapies for NAFLD/NASH.Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
P2860
Q33763305-34F3B47F-CEA7-4EA1-B303-BDDD5203E9A3Q33860008-A3DDB6D1-26BE-4334-AA24-1A2DC4698FC0Q36057947-0FC67009-FE1B-493E-B3C7-0B409195C2F7Q37251449-34347CF5-61A5-4523-BFF6-440BE0A9EDF2Q37381302-2C579498-D3A9-46E3-8871-9FBD9947C5ABQ37685967-F319BE55-E677-4D02-A91E-D584F7AF2314Q38662765-A1F456EB-D979-45B2-9ADE-8A5CEB763875Q38698155-51D84C9F-42ED-4ED6-958E-B06D45C4CAC4Q38778064-4AD6B782-8FC1-4480-9DCC-0E50B92B464CQ39124526-40A73C15-8D47-49C7-9968-7A78A664049BQ41709525-D0AA794E-B41A-4F24-BADE-A2FAFE6F8C61Q42318778-8CF60E91-AFC6-4417-8BBE-9BDFE7DA4BEDQ42404578-1D3C8C93-52BC-4983-8621-BD3C6D2931DEQ43266021-EE51614B-62AA-4F95-8858-71BB09AEC4F2Q47142556-B1188335-C9BE-4189-9DA5-35B9AD21B778Q47778507-BDF22D8E-023F-4E9F-A2F8-37F7E94F563DQ47871089-732972B9-C68E-46E6-B161-223F79E7FC34Q47996942-1C59B6F1-89D8-4FEF-86A3-EE5E0CD80F94Q48103374-420D6261-9BF5-4590-96A4-6D1F7300B724Q48263840-9B581A26-F79C-49C1-9C5C-9429167268DCQ50118123-680EBC6A-F538-45CB-86F0-A0DE1F54BF79Q51034590-0F3097B4-572A-48B0-8826-09FF7AF4E316Q51276351-6F1D8D8F-33CB-4B93-8CDC-8A6A9EBD5382Q52665265-F72389A2-B5FD-4D1E-B749-105CA8C271ECQ55512053-94C23A78-2A78-4CAF-8A74-F2280C8C6F4BQ58740258-3F03533D-F82C-4BB5-B9D8-9A3EE7F049A6
P2860
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@ast
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@en
type
label
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@ast
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@en
prefLabel
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@ast
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@en
P2093
P2860
P1433
P1476
Ipragliflozin Improves Hepatic ...... tive of Body Weight Reduction.
@en
P2093
Chikara Komiya
Kazuo Kanno
Kumiko Shiba
Kyoichiro Tsuchiya
Noriko Shimazu
Shinobu Yamaguchi
Shunsaku Furuke
Yasutaka Miyachi
Yoshihiro Ogawa
P2860
P304
P356
10.1371/JOURNAL.PONE.0151511
P407
P577
2016-03-15T00:00:00Z